Evidence map›Paper›PMID 33430129›Full record

ArticleJournal of personalized medicine2021

A Predictive Model and Risk Factors for Case Fatality of COVID-19.

Melchor Álvarez-Mon, Miguel A Ortega, Óscar Gasulla, Jordi Fortuny-Profitós, Ferran A Mazaira-Font, Pablo Saurina, Jorge Monserrat, María N Plana, Daniel Troncoso, José Sanz Moreno and 5 more

Registry-linked trialAbstract read
In one paragraph

Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06158152 (A Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Systemic Effect on Immunoinflammatory and Metabolic Status of an Oral Supplementation With AM3 in Patients With Metabolic Syndrome.), which is not on this map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06158152 narecruitingnot on this mapstarted 2024, after this paper: background citation

A Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Systemic Effect on Immunoinflammatory and Metabolic Status of an Oral Supplementation With AM3 in Patients With Metabolic Syndrome.

TypeinterventionalSponsorIndustrial Farmacéutica Cantabria, S.A.Ran2024 to 2026Enrolled48ConditionsMetabolic SyndromeArmsAM3 + Probiotic, Placebo, AM3
3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Effectiveness of COVID-19 vaccines and their challenges (Review).Experimental and therapeutic medicine · 2021
    Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Melchor Álvarez-MonService of Internal Medicine and Immune System Diseases-Rheumatology, University Hospital Príncipe de Asturias, (CIBEREHD), 28806 Alcalá de Henares, Spain.
Miguel A OrtegaDepartment of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcalá de Henares, Spain.ORCID 0000-0003-2588-1708
Óscar GasullaHospital Universitari de Bellvitge-Universitat de Barcelona, 08907 L´Hospitalet de Llobregat, Spain.
Jordi Fortuny-ProfitósCampus Nord, Universitat Politècnica de Catalunya, 08034 Barcelona, Spain.ORCID 0000-0002-4181-1593
Ferran A Mazaira-FontDepartament d'Econometria, Estadística I Economia Aplicada-Universitat de Barcelona, 08007 Barcelona, Spain.
Pablo SaurinaUniversidad Complutense de Madrid, 28040 Madrid, Spain.
Jorge MonserratDepartment of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcalá de Henares, Spain.ORCID 0000-0003-1775-4645
María N PlanaService of Internal Medicine and Immune System Diseases-Rheumatology, University Hospital Príncipe de Asturias, (CIBEREHD), 28806 Alcalá de Henares, Spain.
Daniel TroncosoDepartment of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcalá de Henares, Spain.
José Sanz MorenoService of Internal Medicine and Immune System Diseases-Rheumatology, University Hospital Príncipe de Asturias, (CIBEREHD), 28806 Alcalá de Henares, Spain.
Benjamin MuñozService of Internal Medicine and Immune System Diseases-Rheumatology, University Hospital Príncipe de Asturias, (CIBEREHD), 28806 Alcalá de Henares, Spain.
Alberto ArranzService of Internal Medicine and Immune System Diseases-Rheumatology, University Hospital Príncipe de Asturias, (CIBEREHD), 28806 Alcalá de Henares, Spain.
Jose F VaronaService of Internal Medicine, Hospital Universitario HM Montepríncipe, HM Hospitales, 28660 Boadilla del Monte, Spain.ORCID 0000-0003-4764-9440
Alejandro Lopez-EscobarFaculty of Medicine, Universidad San Pablo-CEU, CEU Universities, Fundación de Investigación HM Hospitales, 28003 Madrid, Spain.ORCID 0000-0002-9052-1429
Angel Asúnsolo-Del BarcoRamón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain.ORCID 0000-0001-7898-4685

Funding

ProA Capital 2020
6 · The paper itself

Abstract

This study aimed to create an individualized analysis model of the risk of intensive care unit (ICU) admission or death for coronavirus disease 2019 (COVID-19) patients as a tool for the rapid clinical management of hospitalized patients in order to achieve a resilience of medical resources. This is an observational, analytical, retrospective cohort study with longitudinal follow-up. Data were collected from the medical records of 3489 patients diagnosed with COVID-19 using RT-qPCR in the period of highest community transmission recorded in Europe to date: February-June 2020. The study was carried out in in two health areas of hospital care in the Madrid region: the central area of the Madrid capital (Hospitales de Madrid del Grupo HM Hospitales (CH-HM),

Indexed as

COVID-19C-reactive proteindeathICUoxygen saturationpredictive model

Identifiers

PMID33430129
PMCPMC7827846

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.